Sh-Polypeptide-11 for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4

Also known as: sh-Polypeptide-11, CG-aFGF, rh-Polypeptide-11, rh-Oligopeptide-13, rh-aFGF, FGF1, aFGF, Acidic Fibroblast Growth Factor

Motivation

Sh-Polypeptide-11 is a lab-made copy of a human growth signal (acidic fibroblast growth factor). Cosmetic products put very small amounts into leave-on preparations aimed at thinning hair. The idea is local. Follicles already use growth signals to decide when a hair is made, and this protein is one of those signals.

The protein was developed first for open wounds, not for hair. Interest in hair followed from laboratory and animal work, and from multi-ingredient scalp products that list it beside other growth-signal copies. Pattern hair loss is common with age in both women and men. People focused on long-term health often look at scalp options alongside sleep, food, and training, rather than treating hair as a separate cosmetic problem.

This review examines what Sh-Polypeptide-11 is, how the signal behaves in skin and follicles, which benefits and harms the evidence actually supports, and how products are made, used, and judged. It keeps the hair claim separate from the older wound literature and from marketing language.

Benefits - Risks - Protocol - Conclusion

High-level sources below discuss fibroblast growth factor signaling in the hair cycle, the category this peptide belongs to.

Narrative review of fibroblast growth factors in the hair cycle, including acidic fibroblast growth factor, contrasting pro-growth signals with fibroblast growth factor 5, which ends growth; the authors develop these proteins as drugs.

Fewer than five items qualified. No directly relevant piece was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io. A Life Extension skin article names this growth signal for surface-cell renewal and does not discuss hair. Catalogs and single mouse experiments were not added to fill the list.

Grokipedia

No Grokipedia article on Sh-Polypeptide-11 was found.

Examine

No Examine.com article on Sh-Polypeptide-11 was found.

ConsumerLab

No ConsumerLab article on Sh-Polypeptide-11 was found.

Systematic Reviews

Systematic reviews below include the parent protein among other growth factors for wounds, not Sh-Polypeptide-11 for hair.

Review of topical biologics for diabetic ulcers. Acidic fibroblast growth factor showed slight healing gains in some trials and none in others.

Cochrane review of many growth factors for diabetic foot ulcers, including acidic fibroblast growth factor, not a hair review. Half the trials had industry sponsors.

No systematic review of hair regrowth, and none of adverse events from cosmetic scalp use, was found. Both the claimed hair effect and the main cosmetic risk are unrepresented.

Mechanism of Action

Sh-Polypeptide-11 is a recombinant copy of human acidic fibroblast growth factor (FGF1; the protein this peptide copies). It binds fibroblast growth factor receptors (FGFRs; cell-surface receivers for this signal family) on fibroblasts, surface skin cells, and cells that line small vessels. Heparin, a sugar already in tissue, stabilizes the protein and helps that binding. The receptor then starts a relay that tells the cell to divide.

The family does not point one way in the follicle. Growing human follicles express the gene for this protein (Mitsui et al.). In mice, topical acidic fibroblast growth factor, studied with two related factors by investigators who also develop these proteins as drugs, moved resting follicles into the growth phase earlier than untreated skin and raised beta-catenin (a follicle growth protein) and Sonic hedgehog (Shh; a signal used in follicle growth) sooner (Lin et al.). Fibroblast growth factor 5 helps end that growth phase.

The protein is not selective for one receptor subtype, and it does not cross intact skin in a meaningful amount. In rabbits, none was found in blood after use on intact skin, while wounded skin allowed a small rise nearly gone within three hours (Li et al.). Breakdown is by protein-cutting enzymes, not by cytochrome P450 (CYP; liver enzymes that clear many drugs). In cells, activity fell by half (half-life; time for activity to drop by half) in about seven hours without heparin and about 39 hours with it (Damon et al.). That is not a human blood half-life.

Historical Context & Evolution

The protein was identified as a brain and pituitary extract that made fibroblasts divide, and it was called acidic to set it apart from a basic cousin. Once the human gene was copied into bacteria, a recombinant form was developed as a topical drug for open wounds, not for hair. Sh-Polypeptide-11 is the cosmetic name for a synthetic human version of that same gene product. The “sh-“ mark means synthetic human. It is fermented, not taken from human tissue, and it is used in leave-on products at trace levels.

Hair entered the picture after two findings. Follicles already make the signal while a hair is growing, and mouse skin treated with the recombinant protein entered the growth phase sooner. Patents then placed the ingredient in multi-peptide scalp mixtures. Those documents describe formulas. They are not trials of hair counts. Much of the mouse work and the skin-absorption work comes from groups that also develop fibroblast growth factor drugs, a direct interest in adoption of this protein class.

The picture has not closed, because a human hair comparison has not been done. Wound studies show the pharmaceutical protein can act on open skin, and they do not show what a cosmetic preparation does on an intact scalp. Whether carriers for this large, fragile protein change hair counts is untested. The hair claim is a laboratory rationale plus animal regrowth, beside a separate wound literature.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no hair outcome, and no wound outcome of this protein alone, has been shown in more than one confirmatory human trial.

Medium 🟩 🟩

No benefit reaches Medium: there is no single controlled human trial, and no consistent observational cohort, of Sh-Polypeptide-11 or acidic fibroblast growth factor for a hair outcome.

Low 🟩

Faster Closure of Chronic Wounds ⚠️ Conflicted ⭕️ Not Central to Hair Regrowth

Pharmaceutical acidic fibroblast growth factor, not this cosmetic peptide, was applied to diabetic foot ulcers (Wong et al. systematic review). Some trials showed a slight healing gain and others no difference from placebo. This bears on open wounds, not hair. Overall, the healing signal looks small and inconsistent.

Magnitude: Direction is a small healing gain in some ulcer trials and no clear difference in others, and the literature report no outcome figure for acidic fibroblast growth factor alone.

Speculative 🟨

Earlier Growth-Phase Entry

In mice, topical acidic fibroblast growth factor, with two other factors, brought resting follicles into growth earlier than untreated skin (Lin et al.). No human trial has measured regrowth, so the basis is animal only.

Firmer-Looking Skin ⭕️ Not Central to Hair Regrowth

Seller descriptions tie the protein to firmer skin through fibroblast growth. No human trial of the cosmetic peptide has measured wrinkles, so the basis is mechanistic only, and the claim bears on skin, not hair.

Benefit-Modifying Factors

  • Follicles still present: Mouse data used resting follicles that were still in the skin. A long-smooth bald area may have too few follicles left for a local signal to change what is visible.

  • Baseline density and shed: No blood test predicts a response. People in active thinning have more room to show a change than people whose density has been flat for years.

  • Sex: Pattern hair loss occurs in women and men. No study reports a different response to this peptide by sex.

  • Age: Follicles spend more time at rest with age, including in older adults. No age-specific dose or response is published.

  • Scalp condition: Inflammation, scarring, or a tight scalp changes the tissue the signal meets. The protein does not block androgens (hormones that drive pattern loss).

  • Genetic variants: No variant is known to raise or lower a response to topical Sh-Polypeptide-11.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events of scalp use have not been shown as a human clinical endpoint in more than one trial.

Medium 🟥 🟥

No risk reaches Medium: no single trial and no consistent observational series has measured adverse events of cosmetic scalp use.

Low 🟥

Speculative 🟨

Exposure Through Broken Skin

In rabbits, the protein stayed out of blood on intact skin but entered slightly through wounds and cleared within hours (Li et al.). No human series measured harm, so the basis is animal only.

Unwanted Cell Division

This protein tells fibroblasts and vessel cells to divide, so application over a skin cancer or suspicious spot is an untested risk. No human study has measured that, so the basis is mechanistic only.

Risk-Modifying Factors

  • Broken skin: Wounded rabbit skin absorbed a little; intact skin did not. Cuts, sores, and fresh procedures are the higher-exposure setting.

  • Sex: No difference in adverse events by sex is documented for this peptide.

  • Age: Thinner skin in older adults could raise local exposure. That difference has not been measured.

  • Suspicious lesions: A signal for cell division is a poorer fit over a growing, bleeding, or unhealed scalp spot.

  • Easily irritated skin: People who react to many leave-on products may react to the product base. No human irritation rate for the protein is published.

  • Genetic variants: No variant is known to increase adverse events from topical use.

  • Baseline biomarkers: No blood marker is known to raise or lower harm from topical use. A blood panel is not a risk screen for this peptide.

Key Interactions & Contraindications

  • Heparin and related drugs (heparin, enoxaparin): Caution. In cells, heparin lengthened how long acidic fibroblast growth factor stayed active (Damon et al.). The consequence is a stronger local signal if a heparin dressing covers the same skin. The two are kept apart.

  • Other prescription drugs: No clinical interaction is established. The protein is not cleared by liver drug-metabolizing enzymes, so a metabolism clash is not expected from intact skin.

  • Over-the-counter medicines: None identified.

  • Supplements: None identified in clinical data. Other topical growth-signal products could add to the same pathway. Caution: stacked signaling and irritation. Keeping to one product limits that overlap.

  • Minoxidil: Caution. No drug-level interaction is published. Added scalp irritation is the overlap when two leave-on hair products are used. Separating the applications reduces that overlap.

Populations who should avoid Sh-Polypeptide-11:

  • Active skin cancer, or a scalp lesion that is growing, bleeding, or unhealed: absolute avoidance. The consequence is a cell-division signal on tissue that may already be growing abnormally.

  • Open scalp wounds, including the first days after a procedure: avoidance. Broken skin raised absorption in animals, so exposure is no longer limited to the surface.

  • Pregnancy, any trimester, and lactation: avoidance. No human safety data exist for this exposure.

Risk Mitigation Strategies

  • Intact skin only: Cuts, sores, and fresh procedure sites stay uncovered. This limits the extra absorption seen when skin is broken.

  • Keep off suspicious spots: A growing, bleeding, or unhealed lesion is left uncovered, so a growth signal is not laid on tissue that needs an exam.

  • Small-area start: A coin-sized patch for several days comes before the whole scalp, to catch base irritation early.

  • One growth-signal product: Several growth-factor preparations are not layered. This limits stacked local signaling and irritation.

  • Stop if a reaction persists: Redness, pain, or swelling that continues is a reason to stop, which limits a local adverse event.

  • Separate from heparin dressings: The preparation is not placed under a heparin dressing. This avoids the longer activity heparin produced in cell studies.

Therapeutic Protocol

  • No validated scalp dose: No published protocol gives a microgram dose for hair. Finished products use trace amounts of the fermented protein, often in a carrier, once daily on the scalp.

  • Wound gels are a different product: Pharmaceutical acidic fibroblast growth factor for ulcers is dosed for open wounds. That regimen is not a scalp protocol, and it is not presented here as the default.

  • Where the cosmetic use comes from: Caregen sells the trade material CG-aFGF, and patents describe multi-peptide mixes. No clinic has published a tested single-ingredient hair regimen.

  • Other hair approaches: Minoxidil and finasteride are separate options with their own trials. This peptide is not shown to replace them or to add to them. Neither path is the default here.

  • Time of day: No study compares morning and evening. Activity falls with warmth, so a cool-stored preparation used once daily is the pattern products describe.

  • Half-life: Not measured in human blood after cosmetic use. In wounded rabbits the blood signal was nearly gone by three hours. In cells, activity halved in about seven hours without heparin.

  • Single or split doses: Once daily is the usual cosmetic pattern. Splitting the application has not been compared.

  • Genetic variants: No variant, including drug-metabolism genes, is known to call for a different scalp amount.

  • Sex: No sex-specific amount or response difference is published.

  • Age: No amount change is established for older adults. Follicles at rest for years are a harder setting than early thinning.

  • Baseline state: No lab value sets the amount. Early thinning, with follicles still present, matches the mouse setting better than smooth bald skin.

  • Existing scalp conditions: Active dermatitis, open skin, or a suspicious lesion is outside the setting described for routine cosmetic use.

Discontinuation & Cycling

  • How long: Not established as lifelong or as a fixed course. Products are used for as long as they are continued. No required stop date is described.

  • Withdrawal: No withdrawal syndrome is described. The protein does not build up in the body.

  • Taper: No taper is described. The short local activity does not imply a need to step down.

  • Cycling: Cycling has not been studied. The mouse growth-phase shift was seen during ongoing application, not after an off period.

Sourcing and Quality

  • Identity: A matching label names sh-Polypeptide-11, a fermented copy of human acidic fibroblast growth factor, not a tissue extract. The chain runs up to 155 amino acids.

  • Carrier and heat: The protein is large and heat-fragile. A named carrier, such as a liposome, and cool storage match the known limits on skin entry and stability.

  • Bacterial leftovers: Fermentation can leave endotoxin (debris from bacterial cell walls that can inflame skin). An identity and endotoxin assay is the relevant quality mark. Jars rarely state a microgram amount.

  • Trade material: CG-aFGF is a trade name for this ingredient. A trade name is not independent proof of how much is in a finished product.

Practical Considerations

  • Time to effect: No human timeline is published. The hair cycle is slow, and related scalp products are usually judged over three to six months. An earlier change is not established here.

  • Common pitfalls: Expecting a known hair-count effect; using it on smooth bald skin; confusing it with basic fibroblast growth factor, a different ingredient; storing the container somewhere hot.

  • Regulatory status: In cosmetics it is a leave-on ingredient, not an approved drug for hair loss. A pharmaceutical form used on wounds is a different product and a different amount.

  • Cost and access: Specialty preparations are sold to the public, below surgery prices, and the peptide amount is often undisclosed. Insurers generally pay for neither cosmetic serums nor hair-loss drugs, so coverage does not favor one.

Interaction with Foundational Habits

  • Sleep: Direction: none shown. No study links this preparation to sleep quality. Short sleep and high strain are themselves tied to shedding, which a topical protein has not been shown to offset.

  • Nutrition: Direction: none shown. The peptide does not replace protein, iron, or other building blocks a hair needs. A poor diet can limit growth whatever is on the scalp.

  • Exercise: Direction: none on training adaptation. Cosmetic exposure is not a systemic muscle signal. Sweat or a wash soon after application can remove a leave-on film, so letting it dry comes first.

  • Stress management: Direction: none direct on stress hormones. Strain can push follicles toward shedding through other signals. This protein has not been shown to block that shift.

Monitoring Protocol & Defining Success

Before use, the baseline is a record of the scalp, not a blood panel. Intact skin does not appear to put a meaningful amount of this protein into blood, so routine blood tests are not indicated. Photos in the same light, a count of terminal hairs (thicker, longer hairs) in one marked patch, shaft thickness there, and shed hairs from one standard wash can be recorded. The pattern can be noted in plain words, such as temples, crown, or a widening part. Redness and broken skin belong in that record.

The same photos, patch count, shaft thickness, and wash shed are repeated at 12 weeks and at 24 weeks, then every 6 months if use continues. A new irritation or a sudden shed is a reason to look sooner. Change is read against the person’s own baseline. Usual density varies by scalp site and is not the target.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Terminal-hair density No established target. Track change from the person’s own baseline Shows whether density is rising or falling Same marked site, light, and method each time. A phototrichogram (a close photo count of hairs) helps if available. Usual site counts vary widely and are not a goal.
Hair-shaft diameter No established target. Track change from baseline Thinner shafts mark miniaturization (shafts shrinking in pattern loss) Same fixed point each time. A shift of only a few micrometers can be measurement noise.
Shed hairs per wash No universal optimum. A sustained fall from baseline is the signal Shedding is the change noticed first Same wash method each time. A seasonal shed can mimic a product effect.
  • Shedding on the comb or in the wash: day-to-day variation is large; a trend over many weeks matters more than one wash.

  • Scalp comfort: itch, tightness, flaking, or soreness.

  • Coverage in the same light: the part, the temples, or the crown, compared with the baseline photos.

  • Hair feel: finer or coarser to the touch, which can change before a photo does.

Emerging Research

  • No registered hair trial: A ClinicalTrials.gov search on 26 September 2026 for acidic fibroblast growth factor and hair loss returned no studies. There is no registry record of a human test of the hair claim.

  • Gene delivery is not a serum: In mice, a microneedle patch carrying a virus that makes acidic fibroblast growth factor regrew fur better than the recombinant protein (Zhou et al.). That supports the target in mice and does not test a cosmetic preparation. A human serum result could still be flat.

  • A family member that stops growth: A 2025 review separates pro-growth fibroblast growth factors from fibroblast growth factor 5, which helps end the growth phase (Wang et al.). Success for blockers of that member would narrow, not widen, the case for adding this peptide.

Conclusion

Sh-Polypeptide-11 is a lab-made copy of a human growth signal, used in very small amounts in leave-on hair products. The same protein, in a different pharmaceutical form, has been studied on open wounds. The hair claim is that the signal helps resting follicles start growing again.

What exists for hair is mouse work, plus the fact that growing follicles already make this signal. That is a coherent local story. It is not a count of hairs in people. Another member of the same family pushes follicles to stop growing, so the family is not uniformly helpful. The wound studies, mostly of many growth proteins together, do not line up on ulcer closure and say little about an intact scalp. Exposure through intact skin looks small in animal work, and what does get in is cleared quickly. Harm from cosmetic scalp use has not been measured in people. The open questions are local irritation, broken skin, and a growth signal placed on a spot that is already growing abnormally.

The hair studies and the skin-absorption studies come largely from groups that also develop these proteins as drugs, and wound trials were often industry sponsored. The products are sold by brands with a stake in the ingredient. For someone already paying attention to pattern hair loss, the hair evidence is from animal work and from how the signal behaves, and the wound literature does not settle the cosmetic use.

Top - Benefits - Risks - Protocol